Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement with German pharmaceutical giant Merck KGaA for its in-house developed colony stimulating factor-1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021). According to the agreement, Merck will secure an exclusive license to commercialize pimicotinib in mainland China, Hong Kong, Macau, and Taiwan, and will also receive an exclusive first-refusal option for global commercialization rights outside of these regions. Abbisko will retain responsibility for the development work related to pimicotinib.
Furthermore, Merck has the option to co-develop pimicotinib in additional indications under specific conditions. Merck will make an upfront payment of USD 70 million to Abbisko and provide an additional option fee upon exercising the option. Abbisko is also eligible to receive regulatory and commercial milestones worth up to USD 605.5 million, plus double-digit tiered royalties on net sales by Merck.
Pimicotinib, an orally administered, highly selective, and potent small-molecule antagonist of CSF-1R, is currently under evaluation in a global Phase III clinical trial as a potential therapy for tenosynovial giant cell tumor (TGCT). Beyond TGCT, Abbisko is actively exploring the potential of pimicotinib in treating other indications, including various solid tumors. Abbisko has received approval from the National Medical Products Administration (NMPA) to conduct Phase II clinical studies for pimicotinib in chronic graft-versus-host disease and advanced pancreatic cancer.- Flcube.com
